Lilly/Isis Affinitak Pivotal Trial Fails: Future Rests On Second Phase III Study
Executive Summary
Lilly will await results from a second Phase III Affinitak study before making a final decision regarding its future role in developing Isis' antisense agent for non-small cell lung cancer